Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFS Provident Financial Services Inc

盘后交易 10-07 19:01:34 EDT

21.97

-0.31

-1.39%

盘后21.97

+0.000.00%

16:20 EDT

最高22.11	最低21.80	成交量84.39万
今开22.04	昨收22.28	日振幅1.37%
总市值28.70亿	流通市值27.71亿	总股本1.31亿
成交额1,853万	换手率0.67%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident Financial Services Inc","latestPrice":21.97,"timestamp":1791403200000,"preClose":22.28,"halted":0,"volume":843876,"hourTrading":{"tag":"盘后","latestPrice":21.97,"preClose":21.97,"latestTime":"16:20 EDT","volume":86085,"amount":1891287.45,"timestamp":1791404448414,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01391382405745073,"floatShares":126131374,"shares":130622384,"eps":2.396834,"marketStatus":"盘后交易","change":-0.31,"latestTime":"10-07 19:01:34 EDT","open":22.04,"high":22.105,"low":21.8,"amount":18530912,"amplitude":0.013689,"askPrice":22.3,"askSize":156,"bidPrice":21.64,"bidSize":161,"shortable":3,"etf":0,"ttmEps":2.396834,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791417600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":22.28,"dividendRate":0.043678,"preHourTrading":{"tag":"盘前","latestPrice":22.19,"preClose":22.28,"latestTime":"09:25 EDT","volume":4,"amount":88.76,"timestamp":1791379500026,"change":-0.09,"changeRate":-0.004039,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":21.97,"preClose":21.97,"latestTime":"16:20 EDT","volume":86085,"amount":1891287.45,"timestamp":1791404448414,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.882449,"impliedVol":0.1146,"impliedVolPercentile":0.1275},"requestUrl":"/m/hq/s/PFS","defaultTab":"news","newsList":[{"id":"2669515363","title":"EGFR ex20ins赛道进入冲刺赛：伏美替尼申报一线适应症 国产双药同台竞技","url":"https://stock-news.laohu8.com/highlight/detail?id=2669515363","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669515363?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:19","pubTimestamp":1789975140,"startTime":"0","endTime":"0","summary":"迪哲医药的舒沃替尼、艾力斯的伏美替尼两大国产明星靶向药相继突破，国内EGFR ex20ins治疗格局有望改写。伏美替尼入局20ins一线审批国产双药同台竞技创新药赛道的竞争，本质是时间的竞争。依托WU-KONG28研究的重磅阳性结果，舒沃替尼一线EGFR ex20ins适应症上市申请于2026年5月正式获NMPA受理，并同步纳入优先审评程序。整体来看，2026年底至2027年，国内EGFR ex20ins一线赛道或将迎来双药集中获批的关键窗口期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-21/doc-inisqkzy8948524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4211","IPOS","BK4195","ORR","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668504920","title":"FLAURA2 III期临床研究中国人群亚组OS数据显示 泰瑞沙联合化疗一线治疗EGFR突变晚期非小细胞肺癌总生存期获益趋势与全球保持一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2668504920","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668504920?lang=zh_cn&edition=full","pubTime":"2026-09-18 21:48","pubTimestamp":1789739280,"startTime":"0","endTime":"0","summary":"OS是评估肿瘤患者生存获益的\"金标准\"，此次中国人群OS数据的公布，为该方案在中国EGFR突变晚期肺癌患者中的长生存获益提供了循证依据，进一步证实奥希替尼联合化疗可成为一线标准治疗选择。晚期患者中，奥希替尼在FLAURA III期研究中作为单药疗法，以及在FLAURA2 III期研究中联合化疗，均显示出临床结局改善。作为阿斯利康持续承诺治疗早期肺癌的重要组成部分，ADAURA2 III期临床研究正在进行中，评估奥希替尼用于早期可切除EGFRm NSCLC的辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5051447_ZH51447_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5051447_ZH51447_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4195","LU1829250122.USD","LU2462157665.USD","LU0708994859.HKD","LU0889565916.HKD","LU2468319806.SGD","LU2417539215.USD","LU0058720904.USD","LU2237443622.USD","LU0289739699.SGD","PFS","LU0128525929.USD","LU0432979614.USD","LU2237443382.USD","BK4568","LU2237443895.HKD","LU2237443978.SGD","LU2456880835.USD","LU1267930573.SGD","LU2236285917.USD","LU0029864427.USD","IE00B3T34201.USD","BK4211","AZNH","BK4588","LU0109394709.USD","BK4585","AZN","LU2089984988.USD","BK4007","LU0320765992.SGD","LU0310800379.SGD","LU2237443465.HKD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667367005","title":"优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667367005","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667367005?lang=zh_cn&edition=full","pubTime":"2026-09-16 14:05","pubTimestamp":1789538700,"startTime":"0","endTime":"0","summary":"9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875988974.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163875988974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4211","BK4195","NETL","ADC","PFS","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667696659","title":"靶向HER2的ADC优赫得获新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2667696659","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667696659?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:19","pubTimestamp":1789373969,"startTime":"0","endTime":"0","summary":"靶向HER2的ADC优赫得获新进展","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873441151.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873441151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4211","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810460","title":"和黄医药宣布沃瑞沙®和泰瑞沙®的联合疗法在SAFFRON全球III期研究中显示出具有统计学和临床意义的PFS和OS改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810460","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660810460?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:12","pubTimestamp":1786936320,"startTime":"0","endTime":"0","summary":"继SACHI III期研究支持了该疗法在中国获批后，SAFFRON全球研究的结果进一步印证了其坚实的疗效，并将为泰瑞沙和沃瑞沙联合疗法的全球注册提供明确的数据支持。\" 沃瑞沙和泰瑞沙联合疗法的安全性特征与已知的各药物的安全性保持一致，且没有发现新的安全性问题。基于SACHI III期研究，沃瑞沙和泰瑞沙联合疗法已于中国获批用于治疗接受EGFR TKI治疗后疾病进展的伴有MET扩增的EGFR突变的局部晚期或转移性非小细胞肺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4211","BK4585","BK4195","BK1587","BK4531","BK1588","BK4588","PFS","HCM","BK1191","00013","BK4134","III","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119748217","title":"Provident Financial Services 及其旗下银行联手擢升 Diane Gigliotti 为高级副总裁兼首席会计官","url":"https://stock-news.laohu8.com/highlight/detail?id=1119748217","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119748217?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:31","pubTimestamp":1785875489,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc（简称 Provident）及其附属机构 Provident Bank 近日宣布了一项重要人事任命。Diane Gigliotti 被正式晋升为高级副总裁，并同时担任首席会计官一职。这一举措标志着公司高层管理架构的进一步强化与完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152712915","title":"Provident Financial Services Inc 与 Provident Bank 任命 Michael E. Regan 为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1152712915","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152712915?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:07","pubTimestamp":1785866829,"startTime":"0","endTime":"0","summary":"新泽西州伊瑟林，2026年8月4日——Provident Financial Services Inc及其全资子公司 Provident Bank 今日宣布，自2026年7月30日起，Michael E. Regan 已被任命为公司的董事会成员。“我们很高兴欢迎 Mike 加入 Provident Financial Services 和 Provident Bank 的董事会，”执行董事长 Christopher Martin 表示。“我深感荣幸能够加入 Provident Financial Services 和 Provident Bank 的董事会，”Regan 先生表示。Provident Financial Services Inc 是 Provident Bank 的控股公司，后者是一家自1839年以来提供“值得信赖的承诺”的社区导向型银行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654395072","title":"Sonesitatug vedotin 在 CLDN18.2阳性晚期胃癌/胃食管结合部癌的二线及后线治疗中，显示出具有统计学显著性且重要临床意义的总生存期（OS）改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2654395072","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654395072?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:18","pubTimestamp":1785212280,"startTime":"0","endTime":"0","summary":"关于胃癌和胃食管结合部癌 胃癌是全球第五大常见癌症，也是癌症相关死亡的第五大原因。关键次要终点为二线及后线治疗人群的总生存期。CLDN18.2是一种存在于胃黏膜上皮中的蛋白，已被验证为肿瘤治疗领域的重要治疗靶点，尤其在胃肠道肿瘤中具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AZNH","DEFI","BITY","BFJL","CBOJ","BTCW","BITI","CBXJ","FBTC","CBTO","HODL","BITU","BITX","AZN","PFS","BTC","CBXA","BETH","BTFX","ARKB","ADC","EZBC","EAC","NETL","QBF","BTRN","BITO","BTCO","CBTY","BTCI","XBTY","BTCZ","IBBQ","BETE","HCC","IBIT","CBOA","YBTC","MNRS","BTCL","MAXI","IHC","COAL","BCCC","CBTJ","CBXO","SBIT","CBTA","BRRR","CBXY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183900663","title":"财报前瞻｜Provident Financial Services Inc本季度营收预计温和增长，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1183900663","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183900663?lang=zh_cn&edition=full","pubTime":"2026-07-22 14:35","pubTimestamp":1784702150,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc将于2026年07月29日发布财报，市场聚焦息差与信用成本变动及并表后整合进展。公司未给出本季度毛利率、净利率和净利润的外部一致预测数据，故不展示。主营业务为商业与零售银行相关的“Traditional Banking and Other Financial Services”，上季度该业务收入2.27亿美元。“Traditional Banking and Other Financial Services”为营收主体，营收体量在上季度约2.27亿美元。基于近六个月内公开报道的机构与分析师研判，看多观点占据主导。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Provident Financial Services Inc本季度营收预计温和增长，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652102268","title":"英派药业-B(07630.HK)：多项研究结果摘要获接受于2026年欧洲肿瘤内科学会大会作壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2652102268","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652102268?lang=zh_cn&edition=full","pubTime":"2026-07-20 07:38","pubTimestamp":1784504331,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PFS","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128142903","title":"安东尼·佩特拉祖奥利加入Provident银行，担任存款与支付运营高级副总裁兼总监","url":"https://stock-news.laohu8.com/highlight/detail?id=1128142903","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128142903?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:01","pubTimestamp":1784116897,"startTime":"0","endTime":"0","summary":"安东尼·佩特拉祖奥利已加入Provident银行，被任命为存款与支付运营高级副总裁兼总监。他将负责领导和管理银行的存款与支付相关运营业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PFS","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148362","title":"康方新药取得历史性突破，为何蒸发百亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148362","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641148362?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:42","pubTimestamp":1780659720,"startTime":"0","endTime":"0","summary":"6月1日，康方生物开盘后一度涨超12%，然而高开低走，此后三日连续下跌，截至6月5日收盘，康方生物总市值862亿港元，数日内市值跌去超百亿。在康方生物的叙述中，这份登陆ASCO全体会议的临床数据堪称历史性突破。无可辩驳的是，康方生物的HARMONi-6已达到全部预期终点，取得显著阳性。股价为何下跌数据公布后3日，康方生物的市值跌去超百亿港元，截至发稿，总市值已不足千亿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09926","LU0348827113.USD","LU0348784397.USD","PFS","BK4203","LU2476274308.USD","LU0417516902.SGD","BK4211","BK4225","LU0561508036.HKD","HR","LU2488822045.USD","LU0348766576.USD","BK1574","LU0634319403.HKD","BK4195","LU0417516738.SGD","LU2778985437.USD","IE00B5MMRT66.SGD","02616","LU0348767384.USD","BK1161","LU0540923850.HKD","LU0417516571.SGD","LU1720050803.USD","LU0348735423.USD","LU2399975544.HKD","IE00B543WZ88.USD","LU2476274720.SGD","LU0348783233.USD","LU1961090484.USD","06978","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640493551","title":"死亡风险显著降低34%，广东新药有望定义全球癌症治疗的金标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640493551","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640493551?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:53","pubTimestamp":1780293180,"startTime":"0","endTime":"0","summary":"北京时间5月31日，在2026年美国临床肿瘤学会（ASCO）年会上，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体依沃西新药研究（HARMONi-6研究）成果发布。该新药使得肺鳞癌患者的死亡风险降低34%，同时HARMONi-6研究也是ASCO成立61年来，首个进入全体大会的中国原创新药研究，这意味着中国创新药有能力重新定义全球癌症治疗的金标准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755941315.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755941315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4195","LU0348825331.USD","LU0417516738.SGD","LU1794554557.SGD","BK1574","LU2778985437.USD","LU0348783233.USD","LU2399975544.HKD","LU0417516571.SGD","LU2476274720.SGD","LU0348767384.USD","PFS","06978","LU0348827113.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0348766576.USD","IE00B543WZ88.USD","LU2476274308.USD","BK4211","09926","LU1720050803.USD","LU1961090484.USD","BK1161","LU2488822045.USD","LU0417516902.SGD","LU0348784397.USD","LU0561508036.HKD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640140982","title":"中国生物制药双创新药闪耀ASCO：肺癌一线疗法PFS显著延长，全球首个EGFR/c-Met双抗ADC临床数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2640140982","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640140982?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:47","pubTimestamp":1780278420,"startTime":"0","endTime":"0","summary":"6月1日，中国生物制药（01177）发布公告，旗下附属公司正大天晴药业集团股份有限公司两项重磅创新药临床研究数据，于2026年美国临床肿瘤学会（ASCO）年会正式公布，涵盖肺癌一线治疗与全球首个EGFR/c-Met双抗ADC两大领域，疗效与安全性数据双双亮眼，彰显公司在肿瘤创新药领域的硬核实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755509132.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755509132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1589","BK4211","06978","BK4195","HK0000165453.HKD","BK1191","BK1161","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK4080","PFS","159992","01177","ADC","BK1574","BK1521","IE00BZ08YR35.GBP","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988885","title":"科伦博泰研究成果发表于《柳叶刀》主刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988885","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639988885?lang=zh_cn&edition=full","pubTime":"2026-05-31 19:07","pubTimestamp":1780225625,"startTime":"0","endTime":"0","summary":"5月31日，四川科伦博泰生物医药股份有限公司宣布，其自主研发的抗体偶联药物芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期临床研究成果，正式发表于国际医学期刊《柳叶刀》主刊，研究同时入选2026年美国临床肿瘤学会年会口头报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=Hmeug%2Fbu0FE%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK4225","BK4231","HR","BK4211","BK4080","BK4203","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639641092","title":"港股异动 | 复宏汉霖(02696)午后涨超4% HLX43临床研究完成首例给药 关键PFS数据即将披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2639641092","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639641092?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:18","pubTimestamp":1780035517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖午后涨超4%，截至发稿，涨3.79%，报65.7港元，成交额5153.31万港元。消息面上，复宏汉霖公布，公司创新抗PD-L1抗体偶联药物HLX43用于既往治疗失败的晚期/转移性鳞状非小细胞肺癌治疗的II/III期国际多中心临床研究已在中国完成首例患者给药，标志着该研究在中国正式进入临床实施阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000306701.USD","BK4211","PFS","BK4585","HK0000320223.HKD","VXUS","02696","BK1161","BK4195","HK0000165453.HKD","HK0000320264.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142590005","title":"财报前瞻｜Provident Financial Services Inc本季度营收预计同比增14.74%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1142590005","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142590005?lang=zh_cn&edition=full","pubTime":"2026-04-23 02:37","pubTimestamp":1776883022,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc将于2026年04月29日发布财报，市场预计营收和盈利保持同比增长，净息差与拨备仍是关键变量。市场一致预期本季度Provident Financial Services Inc营收为2.08亿美元，同比增长14.74%；EBIT为1.07亿美元，同比增长13.58%；调整后每股收益为0.55美元，同比增长16.95%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Provident Financial Services Inc本季度营收预计同比增14.74%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473918","title":"来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627473918?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:22","pubTimestamp":1776212528,"startTime":"0","endTime":"0","summary":"II期临床试验是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。.每日一次口服LAE 002的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。本集团有权就许可区域内LAE 002的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002在国际市场的开发及商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","PFS","02105","BK4211","BK1161","BK4195","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517910639","title":"国产双抗疗效击败全球药王 临床研究结果数据已在《柳叶刀》发表了","url":"https://stock-news.laohu8.com/highlight/detail?id=2517910639","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517910639?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:00","pubTimestamp":1741338046,"startTime":"0","endTime":"0","summary":"【国产双抗疗效击败全球药王 临床研究结果数据已在《柳叶刀》发表了】去年9月8日，国产企业康方生物（09926.HK）双抗药物依沃西，从疗效上战胜了全球药王帕博利珠单抗（即“K药”）的消息传开后，引发资本市场沸腾。时至今日，康方生物港股股价涨幅在50%左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503073339808148.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503073339808148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0211331839.USD","LU1941712264.USD","LU0265550359.USD","LU1699723380.USD","LU2089984988.USD","09926","BK4585","IE00BJJMRZ35.SGD","LU2361044949.HKD","LU0070302665.USD","PFS","LU0985320562.USD","LU1093756325.SGD","LU0238689110.USD","LU0320765489.SGD","LU1989771016.USD","SG9999001176.SGD","LU0208291251.USD","LU0348784397.USD","LU0965509010.AUD","IE00B1BXHZ80.USD","LU0265550946.USD","BK1161","SG9999014575.USD","LU0320765646.SGD","BK4534","LU1989772840.SGD","LU1057294990.SGD","LU1116320737.USD","BK4007","LU1066051498.USD","LU1794554557.SGD","LU1720050803.USD","LU2324357040.USD","LU2361044865.SGD","MRK","IE00BBT3K403.USD","SG9999002232.USD","SG9999002224.SGD","BK4550","LU1061106388.HKD","LU1066053197.SGD","LU0203345920.USD","IE00BLSP4239.USD","LU0106261372.USD","LU1023059063.AUD","LU2488822045.USD","SGXZ57979304.SGD","IE000M9KFDE8.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197399939","title":"抵御关税和贸易战风暴，这11只高股息股票或是避风港","url":"https://stock-news.laohu8.com/highlight/detail?id=1197399939","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197399939?lang=zh_cn&edition=full","pubTime":"2025-02-14 13:08","pubTimestamp":1739509687,"startTime":"0","endTime":"0","summary":"关税和贸易战——以及关于关税和贸易战的传闻——将长期存在。股息投资者通常追求稳定性，而美国总统特朗普的贸易政策却截然相反。不过，许多深受投资者喜爱的高股息股票确实存在关税风险。在这一行业框架下，我们可以寻找一些免受关税影响的高股息股票。出人意料的是，其较低的关税风险正是由于其在美国业务和制造规模有限。该公司在2月6日公布了好于预期的盈利和指引后，其股价跃升了11%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/a89ab3e0896a7b709dd40313a2698f0d","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/a89ab3e0896a7b709dd40313a2698f0d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"抵御关税和贸易战风暴，这11只高股息股票或是避风港","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AES","PFS","WTRG","NWE","DTE","EVRG","CVS","NLY","STWD","VNOM"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.provident.bank","stockEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":-0.0607},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.008},{"period":"1year","weight":0.1123},{"period":"ytd","weight":0.1281}],"compareEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.0116},{"period":"3month","weight":0.0452},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1425}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Provident Financial Services, Inc.是一家特拉华州公司，于2003年1月15日成为Provident Bank的控股公司。该公司通过其子公司银行开展业务，该银行是一家面向社区和客户的银行，目前在新泽西州北部和中部以及宾夕法尼亚州的雄鹿县、利哈伊县和北安普敦县以及纽约州的拿骚县和皇后区经营全方位服务的分行和贷款生产办事处。该银行还通过其全资子公司Beacon Trust Company提供信托和财富管理服务，并通过其全资子公司Provident Protection Plus, Inc.提供保险服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.304348,"avgChangeRate":-0.021667},{"month":2,"riseRate":0.375,"avgChangeRate":-0.016026},{"month":3,"riseRate":0.458333,"avgChangeRate":-0.003293},{"month":4,"riseRate":0.5,"avgChangeRate":0.008655},{"month":5,"riseRate":0.458333,"avgChangeRate":-0.011982},{"month":6,"riseRate":0.5,"avgChangeRate":0.002358},{"month":7,"riseRate":0.666667,"avgChangeRate":0.040582},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007764},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.018969},{"month":10,"riseRate":0.666667,"avgChangeRate":0.030963},{"month":11,"riseRate":0.695652,"avgChangeRate":0.033616},{"month":12,"riseRate":0.565217,"avgChangeRate":0.013167}],"exchange":"NYSE","name":"Provident Financial Services Inc","nameEN":"Provident"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Provident Financial Services Inc,PFS,Provident Financial Services Inc股票,Provident Financial Services Inc股票老虎,Provident Financial Services Inc股票老虎国际,Provident Financial Services Inc行情,Provident Financial Services Inc股票行情,Provident Financial Services Inc股价,Provident Financial Services Inc股市,Provident Financial Services Inc股票价格,Provident Financial Services Inc股票交易,Provident Financial Services Inc股票购买,Provident Financial Services Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}